Delayed Pushing Linked to Longer Second Stage of Labor

Share this content:
Delayed Pushing Linked to Longer Second Stage of Labor
Delayed Pushing Linked to Longer Second Stage of Labor

FRIDAY, Oct. 14, 2016 (HealthDay News) -- For nulliparous women, delayed pushing is associated with longer second stage duration and increased odds of cesarean delivery and postpartum hemorrhage, according to a study published in the November issue of Obstetrics & Gynecology.

Lynn M. Yee, M.D., M.P.H., from the Northwestern University in Chicago, and colleagues reviewed data from 21,034 nulliparous women with singleton, cephalic, nonanomalous term births who achieved 10-cm cervical dilation. Outcomes were compared for women in whom pushing was delayed by 60 minutes or more (delayed group; 18.4 percent of the women) and those who initiated pushing within 30 minutes (early group).

The researchers found that delayed pushing was more likely among women who were older, privately insured, or non-Hispanic whites, as well as those who had induction or augmentation of labor, diabetes, or epidural analgesia. Women in the delayed group had longer mean durations of the second stage (P < 0.001) and of active pushing (P < 0.001) after adjustment for differences in baseline and labor characteristics. Delayed pushing correlated with increased rates of cesarean delivery, operative vaginal delivery, postpartum hemorrhage, and blood transfusion (adjusted odds ratios, 1.86, 1.26, 1.43, and 1.51, respectively). Compared with early pushing, delayed pushing was not associated with increased odds of adverse neonatal outcomes.

"These data from a large, contemporary, diverse cohort call attention to the potential risks associated with delayed pushing in the nullipara," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »